A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Kevin Fitzgerald^{1

2}, David Kallend³, Amy Simon¹

Affiliations

Comment

Kevin Fitzgerald et al. N Engl J Med. 2017.

. 2017 May 4;376(18):e38.

doi: 10.1056/NEJMc1703361.

Kevin Fitzgerald^{1

2}, David Kallend³, Amy Simon¹

No abstract available

Comment on

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Masuda S, Miyagawa S, Sawa Y. Masuda S, et al. N Engl J Med. 2017 May 4;376(18):e38. doi: 10.1056/NEJMc1703361. N Engl J Med. 2017. PMID: 28471634 No abstract available.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Koh KK. Koh KK. N Engl J Med. 2017 May 4;376(18):e38. doi: 10.1056/NEJMc1703361. N Engl J Med. 2017. PMID: 28471635 No abstract available.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Lansberg PJ, Banerjee Y. Lansberg PJ, et al. N Engl J Med. 2017 May 4;376(18):e38. doi: 10.1056/NEJMc1703361. N Engl J Med. 2017. PMID: 28471636 No abstract available.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Lancellotti P, Oury C. Lancellotti P, et al. N Engl J Med. 2017 May 4;376(18):e38. doi: 10.1056/NEJMc1703361. N Engl J Med. 2017. PMID: 28471637 No abstract available.